New data indicate Kerendia™ (finerenone) had positive effects on mortality in patients with chronic kidney disease and type 2 diabetes.

Diegem, 8 September, 2022 – Late-breaking data presented today at the European Society of Cardiology (ESC) congress highlight the potential of Kerendia™ (finerenone), compared to placebo, to significantly reduce the incidence of sudden cardiac death across a broad range of patients with early to late-stage chronic kidney disease (CKD) and type 2 diabetes (T2D). While in the overall population of FIDELITY the effect of finerenone on all-cause and CV mortality narrowly missed statistical significance, new data from a prespecified on-treatment analysis from FIDELITY indicate that both of these...